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Abstract 
Citrus aurantium extract has been largely used in weight loss and sports performance dietary 
supplements. However, the safety of C. aurantium-containing products has been questioned 
mainly due to the association of its use with adverse events in the cardiovascular system. 
Therefore, this work aimed to assess the potential for herb-drug interactions among a 
standardized C. aurantium extract (GMP certificate) and amiodarone (narrow therapeutic index 
drug) in rats. In a first pharmacokinetic study, rats were simultaneously co-administered with a 
single-dose of C. aurantium (164 mg/kg, p.o.) and amiodarone (50 mg/kg, p.o.); in a second 
study, rats were pre-treated during 14 days with C. aurantium (164 mg/kg/day, p.o.) and 
received amiodarone (50 mg/kg, p.o.) on the 15th day. Rats of the control groups received the 
corresponding volume of vehicle. Overall, after analysis of the pharmacokinetic data, it deserves 
to be highlighted the significant increase of the peak plasma concentration of amiodarone in rats 
pre-treated with C. aurantium extract, while the extent of systemic exposure was comparable 
between both groups. This paper reports, for the first time, data on the potential of herb-drug 
interaction between C. aurantium extract and amiodarone. However, specific clinical trials 
should be performed to confirm these results in humans. 
 
Keywords: Amiodarone; Citrus aurantium; Herb-drug interaction; Pharmacokinetics; Rats. 
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Abbreviations 
AM, amiodarone; AUC, area under the concentration-time curve; AUC0-t, AUC from time zero to 
the last sampling time; AUC0-∞, AUC from time zero to infinite; Clast, last quantifiable 
concentration; Cmax, peak concentration; CYP, cytochrome P450; FDA, Food and Drug 
Administration; i.p., intraperitoneal; kel, apparent terminal rate constant; LOQ, limit of 
quantification; MDEA, mono-N-desethylamiodarone; MRT, mean residence time; P-gp,  P-
glycoprotein; SD, standard deviation; t1/2el, apparent terminal elimination half-life; tmax, time to 
reach Cmax; UV, ultraviolet detection. 
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1. Introduction 
Citrus aurantium, previously called as Fructus aurantii, is the botanical name of a plant 
commonly known as bitter orange, sour orange, green orange, Seville orange or zhi shi 
(Bouchard et al., 2005; Haaz et al., 2006). The extract of the immature fruit or peel of C. 
aurantium has been widely used in weight loss dietary supplements and in sports performance 
products (Stohs et al., 2011a). In particular, after the ban of the sale of all ephedra-containing 
supplements by the Food and Drug Administration (FDA) in 2004, C. aurantium has gained an 
additional popularity as a safe alternative to Ephedra in herbal weight loss products (FDA and 
HHS, 2004; Hansen et al., 2012; Hansen et al., 2013). C. aurantium has been used as an 
ingredient of the dietary supplements marketed for weight loss aid due to its claimed effects on 
metabolism, increasing the basal metabolic rate and lipolysis, and also as appetite suppressant 
(Stohs et al., 2012). However, C. aurantium has not been traditionally employed for weight loss 
(Haaz et al., 2006). Historically, this herb has been mainly used in traditional Chinese medicine 
to treat gastrointestinal disorders like abdominal distension, dysentery and constipation (Mattoli 
et al., 2005; Stohs et al., 2011a).  
Synephrine, also called p-synephrine or oxedrine, is considered to be the main 
pharmacologically active protoalkaloid present in the extracts of immature fruit or peel of C. 
aurantium, which comprises more than 85% of the total protoalkaloid content. Additionally, other 
minor protoalkaloids constituents include the biogenic amines octopamine, hordenine, tyramine 
and N-methyltyramine (Fugh-Berman and Myers, 2004; Stohs et al., 2011a; Hansen et al., 
2012). Structurally, synephrine is closely related to ephedrine (one of the main active 
constituents found in the genus Ephedra) (Hansen et al., 2012; Hansen et al., 2013). However, 
despite their great structural similarities, synephrine contrary to ephedrine seems to exhibit little 
or no stimulant activity on the cardiovascular and central nervous system; the small chemical 
differences between synephrine and ephedrine also appear to significantly change their 
pharmacokinetic properties, particularly their ability to cross the blood-brain barrier (Stohs et al., 
2011b). Based on receptor binding studies, synephrine exhibited poor affinity for β-1, β-2 and α-
adrenoreceptors, which are usually associated with cardiovascular effects (particularly β-1 and 
α-adrenoreceptors); instead, synephrine showed β-3 adrenergic activity which is responsible for 
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increased thermogenesis and lipolysis (Stohs et al., 2011a). Even so, the safety and efficacy of 
supplements containing C. aurantium have been questioned (Bent et al., 2004; Fugh-Berman 
and Myers, 2004). 
A large number of case reports have emerged over the last years associating the use of C. 
aurantium-containing products with serious clinical adverse events, most of them involving the 
cardiovascular system, such as syncope and prolongation of the QT interval (Nasir et al., 2004), 
myocardial infarction (Nykamp et al., 2004; Thomas et al., 2009), ischemic stroke (Bouchard et 
al., 2005), angina (Gange et al., 2006) and tachycardia (Firenzuoli et al., 2005), bradycardia and 
hypotension (Gray and Woolf, 2005), vasospasm and stroke (Holmes Jr. and Tavee, 2008), 
ventricular fibrillation (Stephensen and Sarlay Jr., 2009) and ischemic colitis (Sultan et al., 
2006). Furthermore, a pharmacokinetic herb-drug interaction involving a decoction of C. 
aurantium and cyclosporine was also reported (Hou et al., 2000). 
Hence, considering that C. aurantium has been extensively used as a replacement of Ephedra 
in the composition of weight loss dietary supplements and considering that the obesity and 
overweight are increasing at an alarming rate (Pittler et al., 2005), representing major 
independent risk factors for cardiovascular diseases (Scaglione et al., 2004; Bodary et al., 2007; 
Zalesin et al., 2011), an increase on the consumption of herbal supplements containing C. 
aurantium is still expected. Thus, as the concurrent use of these herbal products and 
conventional drugs may lead to significant clinical herb-drug interactions, it is therefore 
absolutely pertinent to investigate the potential for pharmacokinetic interactions between C. 
aurantium and narrow therapeutic index drugs, as is the case of amiodarone. 
Amiodarone [2-n-butyl-3-(3,5-diiodo-4-diethylaminoethoxy-benzoyl)-benzofuran; (Fig. 1)] still 
remains one of the most widely prescribed antiarrhythmic drugs for the treatment of atrial 
fibrillation and ventricular arrhythmias despite the availability of novel antiarrhythmic agents 
(Papiris et al., 2008). From a pharmacological viewpoint amiodarone has unusual and complex 
pharmacokinetic properties (Shayeganpour et al., 2008; van Herendael and Dorian, 2010). 
Amiodarone has a variable oral bioavailability (20-80%) and the great lipophilicity of amiodarone 
and its main metabolite [mono-N-desethylamiodarone (MDEA)] (Fig. 1) leads to a high volume 
of distribution and a variable accumulation into tissues (van Herendael and Dorian, 2010). 
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MDEA is the product of the most predominant metabolic route of amiodarone, the N-
deethylation which is catalyzed by cytochrome P450 (CYP) isoenzymes (Trivier et al., 1993; 
Soyama et al., 2002). Moreover, amiodarone is recognised as a drug of narrow therapeutic 
window (0.5–2.0 μg/mL) (Pérez-Ruiz et al., 2002; Shayeganpour et al., 2008) and it has also 
been associated to important clinical drug interactions (Siddoway, 2003; Edwin et al., 2010; 
Karimi et al., 2010; Roughead et al., 2010).  
Taking into account all the reasons previously referred and bearing in mind the potential for co-
administration of C. aurantium medicinal products and amiodarone, this work was planned to 
investigate if a standardized extract of the green fruit of C. aurantium may influence the 
pharmacokinetics of amiodarone in rats, following their simultaneous oral co-administration, and 
after a 14-day C. aurantium pre-treatment period. 
 
2. Materials and methods 
2.1. Drugs and materials 
C. aurantium hidroalcoholic extract 10% synephrine (11.1% synephrine by high-performance 
liquid chromatography-ultraviolet detection batch analysis; approximately 94% of the total 
content in potent amines consists of synephrine) obtained from green fruit was purchased from 
Bio Serae Laboratories (Bram, France); the corresponding certificate of analysis ref. 410039 
(batch 0907799) is provided as Supplementary data. Carboxymethylcellulose sodium salt for 
preparation of extract suspension was obtained from Sigma (St. Louis, MO, USA). A 
commercial formulation (ampoules) of amiodarone hydrochloride 50 mg/mL solution for 
intravenous injection was used for oral administration to rats after appropriate dilution with 5% 
glucose intravenous solution for infusion (B. Braun Medical, Portugal). Other compounds used 
were sodium chloride 0.9% solution for injection (Labesfal, Portugal); heparin sodium 5000 
U.I./mL for injection (B. Braun Medical, Portugal); ketamine for injection (Imalgene 1000) and 
xylazine for injection (Vetaxilaze 20). Introcan® Certo IV indwelling cannula (22G; 0.9 x 2.5 mm) 
made of polyurethane from B. Braun Melsungen AG (Melsungen, Germany). 
 
2.2. Animals   
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Adult male Wistar rats (361 ± 26 g) of approximately 10 weeks old were obtained from local 
animal facilities (Faculty of Health Sciences of the University of Beira Interior, Covilhã, 
Portugal). The rats were maintained under controlled environmental conditions (temperature 20 
± 2 ºC; relative humidity 55 ± 5%; 12-h light/dark cycle). The animals were allowed free access 
to a standard rodent diet (4RF21, Mucedola, Italy) during almost all experimental procedures 
and tap water was available ad libitum. At night on the day before dosing with amiodarone, a 
lateral tail vein of each rat was cannulated, under anaesthesia [ketamine (90 mg/kg)/xylazine 
(10 mg/kg); i.p. injection], by insertion of an Introcan® Certo IV indwelling cannula (22G; 0.9 x 
2.5 mm) used for serial blood sampling. The rats fully recovered from anaesthesia overnight 
and were fasted for 12-14 h before amiodarone administration and maintained with free access 
to water; in order to avoid the effect of food on the oral bioavailability of amiodarone an 
additional fasting period was considered (4 h post-dose). Oral treatments of the rats with C. 
aurantium extract and amiodarone were performed by gavage. Blood sampling was conducted 
in conscious and freely moving rats, which were appropriately restrained only at the moment of 
blood collection, except for the last blood sampling that was taken by a terminal procedure 
(decapitation and exsanguination under anaesthesia). All the animal experiments were 
conducted in accordance with the European Directive (2010/63/EU) for the accommodation and 
care of laboratory animals and the experimental procedures were reviewed and approved by 
the Portuguese Veterinary General Division. 
 
2.3. Experimental design and pharmacokinetic studies 
Two separate and independent pharmacokinetic studies were designed to investigate the 
effects of C. aurantium on the kinetics of amiodarone: (1) a single oral co-administration study 
of C. aurantium extract and amiodarone; and (2) a 14-day repeated oral pre-treatment study 
with C. aurantium extract and on the 15th day a single oral dose of amiodarone was given. The 
dose of C. aurantium was selected based on the dose recommended to humans by the supplier 
of the extract (Bio Serae Laboratories) and taking into account the FDA Guidance for Industry 
on conversion of animal doses to human equivalent doses, which considers the body surface 
area (US DHHS, FDA, CDER, 2005); additionally, a 10-fold potentiating interaction factor was 
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applied. The experimental dose of herbal extract selected is greater than the typical human 
daily dose to avoid false negative results and considering potential differences in the 
extrapolation between species (rat versus human). On the other hand, the single oral dose of 
amiodarone (50 mg/kg) was established because it has provided plasma concentrations of 
amiodarone in rats within the plasma therapeutic range (Shayeganpour et al., 2005). In each 
day of the experiments C. aurantium extract was suspended in 0.5% carboxymethylcellulose 
aqueous solution affording a suspension of herbal extract at 16.4 mg/mL. Amiodarone 
commercial injectable solution (50 mg/mL) was also appropriately diluted with 5% glucose 
solution to extemporaneously prepare an amiodarone solution at 12.5 mg/mL. Appropriate 
volumes of C. aurantium extract suspension (10 mL/kg of body weight) and of amiodarone 
solution (4 mL/kg of body weight) were orally administered to rats by oral gavage. 
In the first pharmacokinetic study, twelve Wistar rats were randomly divided into two groups 
(experimental and control groups). The rats of the experimental group (n = 6) were 
concomitantly treated with a single-dose of C. aurantium extract (164 mg/kg, p.o.) and a single-
dose of amiodarone (50 mg/kg, p.o.); the extract suspension was administered just before 
amiodarone. The rats of the control group (n = 6) received, instead of the C. aurantium extract 
suspension, the corresponding volume of 0.5% carboxymethylcellulose aqueous solution 
(vehicle of the extract). 
In the second pharmacokinetic study, twelve Wistar rats were also randomly divided into two 
groups. The rats assigned to the experimental group (n = 6) were orally pre-treated with C. 
aurantium extract (164 mg/kg, p.o.) once daily for 14 consecutive days (short-term repeated 
dose pre-treatment study), whereas the rats allocated to the control group (n = 6) were 
administered with an equivalent volume of vehicle for the same period of time. During the pre-
treatment period, the rats were kept in 12-h light/dark cycle animal room with controlled 
temperature and humidity, as indicated above (see Section 2.2.); free access to a standard 
rodent diet and tap water was allowed. On 15th day, the rats of both groups (experimental and 
control) were gavaged with a single-dose of amiodarone (50 mg/kg, p.o.).  
In both pharmacokinetic studies the treatments with C. aurantium extract (or vehicle) and/or 
amiodarone were always carried out on the morning between 9:00 am and 11:45 am. At night 
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on the day before amiodarone administration, the rats were anaesthetized for cannulation of a 
lateral tail vein and were fasted overnight as described above (see Section 2.2.). On the day 
after, multiple serial blood samples (approximately 0.3 mL) were collected through the cannula 
into heparinized tubes before dosing and at 0.25, 0.5, 1, 2, 4, 6, 8 and 12 h following 
amiodarone administration; the blood samples were collected from all 6 rats in each treatment 
group at each time-point. Then, at 24 h post-dose, blood and tissues (heart, liver, kidneys and 
lungs) were also harvested after decapitation of the rats. The blood samples were centrifuged at 
4000 rpm for 10 min (4 ºC) to separate the plasma which was stored at –20 ºC until analysis. 
After exsanguination, liver, kidneys, heart and lungs were excised and stored at –20 ºC; the 
organs were weighed and homogenized in distilled water (3 mL of water per gram of tissue) 
before analysis of tissue homogenates samples. 
 
2.4. Drug analysis 
Plasma and tissue concentrations of amiodarone and its main metabolite MDEA were 
determined by using a liquid-liquid extraction procedure coupled to the high-performance liquid 
chromatography-diode array detection assay previously developed and validated (Rodrigues et 
al., 2013a).  
 
2.5. Pharmacokinetic analysis 
The plasma concentration versus time data for amiodarone and MDEA obtained from each 
individual rat were submitted to a non-compartmental pharmacokinetic analysis using the 
WinNonlin® version 4.1 (Pharsight Co, Mountain View, CA, USA). The peak concentrations of 
amiodarone and MDEA in plasma (Cmax) and the time to reach Cmax (tmax) were directly obtained 
from the experimental data. Other pharmacokinetic parameters estimated from the individual 
plasma concentration-time profiles  were: area under the concentration-time curve (AUC) from 
time zero to the last sampling time at which concentrations were at or above the limit of 
quantification (LOQ; 0.100 µg/mL) of the method (AUC0-t), calculated by the linear trapezoidal 
rule; AUC from time zero to infinite (AUC0-∞), calculated from AUC0-t + (Clast/kel), where Clast is 
the last quantifiable concentration and kel is the apparent terminal elimination rate constant 
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calculated by log-linear regression of the terminal segment of the concentration-time profile; 
apparent terminal elimination half-life (t1/2el) and mean residence time (MRT). The 
concentrations lower than the LOQ of the assay were taken as zero for all calculations. 
 
2.6. Short-term repeated dose effect of C. aurantium on body weight 
In the pre-treatment study (a 14-day C. aurantium treatment period), the body weight of the rats 
administered with C. aurantium extract (164 mg/kg/day, p.o.; experimental group) or vehicle 
(control group) was adequately registered on the first day and on the last day (14th) of the 
treatments in order to evaluate the effect of C. aurantium extract on body weight changes. 
 
2.7. Statistical analysis 
Data were reported as the mean ± standard deviation (SD). Comparisons between two groups 
were usually performed using unpaired two-tailed Student’s t-test; for body weight comparisons 
within the same group the paired Student’s t-test was employed. A difference was considered to 
be statistically significant for a p-value lower than 0.05 (p < 0.05). 
 
3. Results 
3.1. Simultaneous co-administration of C. aurantium and amiodarone  
The mean plasma concentration-time profiles (n = 6) of amiodarone and its main metabolite 
(MDEA) obtained after the intragastric simultaneous co-administration of rats with a single-dose 
of C. aurantium extract (164 mg/kg, p.o.) or vehicle (control group) and a single-dose of 
amiodarone (50 mg/kg, p.o.) are shown in Figure 2. Overall, the mean plasma concentrations of 
amiodarone were found to be statistically different only at 24 h post-dose (p < 0.001). In the 
case of MDEA, the plasma concentrations were similar in both groups, with values near or 
below the LOQ (0.100 μg/mL) of the method. The mean plasma pharmacokinetic parameters 
estimated for amiodarone and MDEA after non-compartmental analysis of each individual 
concentration-time profile are summarized in Table 1. From the observation of mean plasma 
concentration-time profiles of amiodarone (Fig. 2), it is evident that the time to reach Cmax (tmax) 
was attained later in the experimental (C. aurantium) group than in the control (vehicle) group.  
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However, no statistically significant differences in the mean pharmacokinetic parameters for 
amiodarone were detected among the two groups (C. aurantium versus vehicle) (Table 1). 
These data show that the treatment of rats with C. aurantium extract does not significantly affect 
the extent of systemic exposure to amiodarone (as assessed by AUC), but the maximum 
exposure to the drug is delayed.  Considering the scarcity of quantifiable plasma concentrations 
obtained for MDEA in both groups, only the Cmax and tmax pharmacokinetic parameters are 
presented in Table 1. 
To examine the biodistribution of amiodarone and MDEA in rats, either in the presence or 
absence of the co-administration with C. aurantium, at 24 h after dosing all animals were 
sacrificed and several organs were excised and analysed. The mean concentrations of 
amiodarone and MDEA determined in heart, lung, liver and kidney tissues, and also the plasma 
concentrations at the same time (24 h), are shown in Figure 3. The tissue concentrations of 
amiodarone and MDEA were markedly higher than those measured in plasma, and the 
concentration levels found for both compounds (amiodarone and MDEA) in the lung tissue were 
absolutely noteworthy. However, despite the significant differences detected at 24 h  post-dose 
for amiodarone plasma concentrations (p < 0.001), at the same time only for heart tissue were 
also found statistically significant differences (p < 0.05), and the concentrations of amiodarone 
were higher in the group of rats treated with the extract. 
 
3.2. Short-term repeated dose pre-treatment study with C. aurantium followed by amiodarone 
administration 
The rats were administered for 14 days with C. aurantium extract (164 mg/kg/day, p.o.; 
experimental group) or vehicle (control group) in order to investigate a possible interference of 
the short-term repeated dose pre-treatment with the extract on the pharmacokinetics of 
amiodarone. The day after the last treatment with C. aurantium extract or vehicle, all animals 
received a single-oral dose of 50 mg/kg amiodarone and the mean plasma concentration-time 
profiles (n = 6) of the drug and its main metabolite (MDEA) are depicted in Figure 4. Comparing 
the mean plasma concentrations for amiodarone in both groups, they were found to be 
statistically different only at 2 h post-dose (p < 0.05), and they were higher in the group treated 
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with C. aurantium. The mean plasma pharmacokinetic parameters for amiodarone and MDEA 
determined by applying non-compartmental analysis to each individual concentration-time 
profile are listed in Table 2. The pre-treatment with C. aurantium extract determined a 
significantly higher Cmax value for amiodarone (p < 0.01), while for the other pharmacokinetic 
parameters no significant differences were found between both groups. Hence, from the data 
shown in Table 2, it is evident that the degree of systemic exposure to amiodarone (as 
assessed by Cmax) is higher in the rats pre-treated with C. aurantium extract comparatively with 
those of the control group, whereas the extent of systemic exposure to amiodarone is similar 
among experimental and control groups (ratios near to unity; as assessed by AUC0-t and AUC0-
∞
). The plasma concentrations of MDEA were near or below the LOQ (0.100 μg/mL) of the 
method in both groups. 
To investigate the influence of a 14-day pre-treatment period with C. aurantium extract 
(experimental group) or vehicle (control group) on the distribution and metabolism of 
amiodarone in rats, the concentrations of amiodarone and its major metabolite (MDEA) were 
also determined in various tissues (additionally to plasma) at 24 h post-dose and the results are 
shown in Figure 5. The concentrations of both compounds (amiodarone and MDEA) in tissues 
were manifestly greater than those measured in plasma, and the concentration levels found in 
lung tissue were extremely high in both experimental (C. aurantium) and control (vehicle) 
groups. However, at 24 h post-dose, no significant differences were observed for amiodarone 
and MDEA concentrations between both groups (AM Citrus versus AM Vehicle). 
  
3.3. Short-term repeated dose effect of C. aurantium on body weight 
In the rats submitted to a 14-day pre-treatment period with C. aurantium extract (164 mg/kg/day, 
p.o) or vehicle was found a statistically significant increase in body weight in both groups. In the 
group of rats treated with C. aurantium extract was observed an increase of the body weight 
from 366.17 ± 18.76 g to 379.00 ± 21.93 g (p < 0.05) and in the control (vehicle) group the body 
weight of the rats increased from 355.33 ± 28.45 g to 367.67 ± 23.51 g (p < 0.01) between the 
1st and 14th day of the experiments. Furthermore, the increase in body weight of the rats of both 
groups (C. aurantium versus vehicle) was comparable (12.83 ± 8.13 g versus 12.33 ± 6.41 g, p 
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> 0.05). Hence, under these experimental conditions, the C. aurantium extract was shown to be 
ineffective to control the body weight gain in rats.  
 
4. Discussion 
Over the last years several interactions have been reported in literature describing the 
interference of herbal products and other compounds on the pharmacokinetics of amiodarone. 
For instance, the grapefruit juice dramatically inhibited the metabolism of amiodarone (Libersa 
et al., 2000), the co-administration of orlistat and amiodarone significantly reduced the systemic 
exposure to amiodarone and its main metabolite MDEA (Zhi et al., 2003), the exposure of rats 
to β-naphthoflavone (a polycyclic aromatic hydrocarbon) was found to increase the formation of 
MDEA probably through CYP induction (Elsherbiny et al., 2010) and, more recently, our 
research group documented the occurrence of herb-drug interactions between Fucus 
vesiculosus extract or Paullinia cupana extract and amiodarone in rats (Rodrigues et al., 2012; 
Rodrigues et al., 2013b). 
Accordingly, the present work was delineated to investigate the potential of interaction between 
C. aurantium extract and amiodarone in vivo, using adult male Wistar rats. The pharmacokinetic 
studies herein reported were designed to examine the interference of C. aurantium extract on 
the gastrointestinal absorption (simultaneous co-administration study) and on the metabolism of 
amiodarone (14-day C. aurantium pre-treatment study). In fact, drug-drug or herb-drug 
interactions mainly occur at the level of absorption process and/or metabolic (inhibition or 
induction) pathways. 
Overall, our results show that the simultaneous co-administration of a single-dose of C. 
aurantium extract and amiodarone caused an apparent delay to reach the peak plasma 
concentration of the drug, but it did not change significantly the level and the extent of systemic 
exposure
 
to amiodarone (as assessed by Cmax and AUC0-t, respectively). This increase in the 
time to achieve Cmax is not expected to alter the efficacy of amiodarone and it is unlikely to be 
clinically important. At this point, it deserves to be mentioned that after the co-administration of 
amiodarone with other herbal extracts (Fucus vesiculosus extract and Paullinia cupana extract), 
which are also claimed to be useful for weight loss, a delay in the time to reach Cmax was also 
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observed; however, in these studies a significant decrease in the systemic exposure to 
amiodarone was clearly evident in the rats treated with herbal extracts (Rodrigues et al., 2012; 
Rodrigues et al., 2013b). 
Moreover, because of the central role that the induction of CYPs and P-glycoprotein (P-gp) 
plays on drug-drug and herb-drug interactions, and bearing in mind that the induction 
mechanisms are time-dependent, the interference of C. aurantium extract on the 
pharmacokinetics of amiodarone was also investigated by administering the extract for 14 
consecutive days (164 mg/kg/day, p.o.) until 24 h before applying amiodarone. In fact, 
amiodarone is metabolized by several CYP isoenzymes including CYP1A1/2, CYP2C8, 
CYP2C19, CYP2D6 and CYP3A4 (Ohyama et al., 2000; Elsherbiny et al., 2010) and is a 
substrate of P-gp (Shapiro and Shear, 2002; Kalitsky-Szirtes et al., 2004). The only significant 
change was an increase in the level of systemic exposure to amiodarone (as assessed by Cmax) 
in the rats pre-treated during 14 days with C. aurantium extract (versus vehicle). No significant 
differences were found in the extent of systemic drug exposure (as assessed by AUC0-t and 
AUC0-∞). Therefore, to explain the increase of the Cmax in the group of rats pre-treated with C. 
aurantium we hypothesise that the extract or some of its constituents could change (increase) 
the gastrointestinal motility, thus increasing the rate at which amiodarone passes to the 
intestine. Actually, the absorption of amiodarone across the intestinal membrane occurs by 
passive diffusion, which is a non-saturable process (Martín-Algarra et al., 1997). According to 
the studies of Jinzhao et al. (2005), the C. aurantium may improve the gastric emptying in rats 
with functional dyspepsia. Furthermore, extracts of C. aurantium also increased the rate of 
gastrointestinal motility enhancing, therefore, the absorption function of gastrointestinal tract (Li 
et al., 2007). In addition, C. aurantium can also antagonise the inhibition of the intestinal 
advance induced by atropine (Xue-Bao et al., 2005). In a study conducted by Fang et al. (2009) 
the effects of constituents of C. aurantium on the gastrointestinal movement were evaluated; the 
hesperidin had a stimulatory effect on the gastrointestinal muscle contraction while synephrine 
had an inhibitory effect.  
Another possibility to explain the higher Cmax values for amiodarone in the group of rats pre-
treated with C. aurantium extract could be related to a time-dependent inhibitory effects induced 
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by C. aurantium or some of its phytochemicals on the CYPs and/or P-gp–mediated efflux 
activity. Actually, in a non-clinical study was reported that a decoction of C. aurantium increased 
the bioavailability of cyclosporine (Hou et al., 2000).  
Based on the herb-drug interaction data obtained in the present work involving C. aurantium 
and amiodarone, it is suggested that the tested C. aurantium extract has no significant impact 
on the pharmacokinetic of amiodarone, even using an experimental dose of extract in rats 
higher than the typical recommended dose in humans. Even so, it should be taken in account 
that results from animal experiments cannot be directly extrapolated to humans; however, 
bearing in mind the studies of Shayeganpour et al. (2005) and Meng et al. (2001), the rat 
appears to be an appropriate animal model for man in this case. Nevertheless, to reliably 
assess the safety of the administration of C. aurantium extract and amiodarone specific clinical 
trials are required. 
Additionally, in our study the increase of body weight of the rats pre-treated with C. aurantium 
extract or vehicle was comparable. These data are in accordance with other results found in the 
literature for C. aurantium extract. Arbo et al. (2008) also reported that the body weight gain did 
not change significantly comparing with the control group in rats treated during 28 days with 
400, 2000 and 4000 mg/kg of C. aurantium extract. Only was observed a reduction in the gain 
of body weight for rats treated with 30 and 300 mg/kg of synephrine during 28 days (Arbo et al., 
2008). 
 
5. Conclusions 
In conclusion, no significant effects were observed on the pharmacokinetics of amiodarone in 
rats after the simultaneous co-administration in single-dose of C. aurantium extract and 
amiodarone. On the other hand, following a 14-day pre-treatment period with C. aurantium 
extract a marked increase in the peak plasma concentrations of amiodarone was observed, but 
this did not show any significant impact in the extent of systemic exposure to amiodarone. 
Therefore, C. aurantium extract seems to have only minor effects on the pharmacokinetics of 
amiodarone in rats. However, it is important to be aware that this work only provides a non-
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clinical proof of the effects of C. aurantium fruit extract on the pharmacokinetics of amiodarone. 
Thus, aiming at confirming these results in humans a thorough clinical trial is required.  
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Figure captions 
Fig. 1. Chemical structures of amiodarone (AM) and its major metabolite mono-N-
desethylamiodarone (MDEA). 
 
Fig. 2. Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats simultaneously treated 
in single-dose with Citrus aurantium extract (164 mg/kg, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Symbols 
represent the mean values ± standard deviation (SD) of six determinations per time point (n = 
6). #p < 0.001 compared to control (vehicle). 
 
Fig. 3. Mean plasma and tissue (heart, lung, liver and kidney) concentrations of amiodarone 
(AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, from rats 
simultaneously treated in single-dose with Citrus aurantium extract (164 mg/kg, p.o.), or vehicle 
(0.5% carboxymethylcellulose aqueous solution), and AM (50 mg/kg, p.o.) by oral gavage. Data 
are expressed as the mean values ± standard deviation (SD) of six determinations (n = 6). *p < 
0.05 and #p < 0.001 compared to control (vehicle). 
 
Fig. 4. Mean plasma concentration-time profiles of amiodarone (AM) and mono-N-
desethylamiodarone (MDEA) obtained, over a period of 24 h, from rats submitted to a 14-day 
pre-treatment period with Citrus aurantium extract (164 mg/kg/day, p.o.), or vehicle (0.5% 
carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose of AM 
(50 mg/kg, p.o.) by oral gavage (n = 6). Symbols represent the mean values ± standard 
deviation (SD) of six determinations per time point (n = 6). *p<0.05 compared to control 
(vehicle). 
 
Fig. 5. Mean plasma and tissue (heart, lung, liver and kidney) concentrations of amiodarone 
(AM) and mono-N-desethylamiodarone (MDEA) obtained, at 24 h post-dose, from rats 
submitted to a 14-day pre-treatment period with Citrus aurantium extract (164 mg/kg/day, p.o.), 
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or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a 
single-dose of AM (50 mg/kg, p.o.) by oral gavage. Data are expressed as the mean values ± 
standard deviation (SD) of six determinations (n = 6).  
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Table 1 – Mean pharmacokinetic parameters estimated by non-compartmental analysis of the plasma 
concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone (MDEA, major metabolite of 
AM) obtained in rats after the simultaneous co-administration in single-dose of Citrus aurantium extract (164 
mg/kg, p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), with AM (50 mg/kg, p.o.) by oral 
gavage (n = 6, unless otherwise noted). 
AM Citrus  AM Vehicle Parameter 
AM MDEA  AM MDEA 
tmax (h) 3.17 ± 1.83 12.00 ± 0.00a  1.83 ± 1.17 7.20 ± 3.03b 
Cmax (μg/mL) 1.405 ± 0.425 0.109 ± 0.008a  1.378 ± 0.439 0.125 ± 0.027b 
AUC0-t (μg.h/mL) 16.417 ± 3.805 ND  12.774 ± 1.685 ND 
AUC0-∞ (μg.h/mL) 25.797 ± 2.903 ND  21.431 ± 5.088 ND 
kel (h-1) 0.0472 ± 0.0168 ND  0.0433 ± 0.0201 ND 
t1/2el (h) 16.57 ± 6.82 ND  20.73 ± 14.05 ND 
MRT (h) 24.63 ± 10.59 ND  28.64 ± 18.95 ND 
ND, not determined. 
an = 2; bn = 5 
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Table 2 – Mean pharmacokinetic parameters estimated by non-compartmental analysis of the plasma 
concentration-time profiles of amiodarone (AM) and mono-N-desethylamiodarone (MDEA, major metabolite of 
AM) obtained in rats submitted to a 14-day pre-treatment period with Citrus aurantium extract (164 mg/kg/day, 
p.o.), or vehicle (0.5% carboxymethylcellulose aqueous solution), and treated on the 15th day with a single-dose 
of AM (50 mg/kg, p.o.) by oral gavage (n = 6, unless otherwise noted). 
 
ND, not determined. 
an = 2; bn = 4. 
* p < 0.01, significantly different from the control group. 
 
AM Citrus  AM Vehicle Parameter 
AM MDEA  AM MDEA 
tmax (h) 2.67 ± 1.51 7.00 ± 1.41a  2.00 ± 1.55 9.00 ± 4.24b 
Cmax (μg/mL) 1.654 ± 0.253* 0.107 ± 0.004a  1.046 ± 0.371 0.106 ± 0.008b 
AUC0-t (μg.h/mL) 14.318 ± 2.837 ND  12.282 ± 2.564 ND 
AUC0-∞ (μg.h/mL) 23.901 ± 9.914 ND  22.057 ± 7.115 ND 
Kel (h-1) 0.0485 ± 0.0182 ND  0.0442 ± 0.0265 ND 
t1/2el (h) 16.38 ± 7.18 ND  21.62 ± 14.34 ND 
MRT (h) 23.97 ± 9.52 ND  31.02 ± 20.31 ND 
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Highlights  
► For the first time data on the potential of interaction between C. aurantium extract and 
amiodarone is reported. 
► The simultaneous oral co-administration of C. aurantium extract and amiodarone induced a 
delay in the tmax of the drug. 
► A 14-day oral pre-treatment with C. aurantium extract induced a significant increase in the 
Cmax of amiodarone. 
► The extent of systemic exposure to amiodarone was not affected by the co-administration or 
pre-treatment with C. aurantium. 
 
 
